These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 29420117)
1. Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. Thepmalee C; Panya A; Junking M; Chieochansin T; Yenchitsomanus PT Hum Vaccin Immunother; 2018 Jun; 14(6):1423-1431. PubMed ID: 29420117 [TBL] [Abstract][Full Text] [Related]
2. Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells. Thepmalee C; Panya A; Sujjitjoon J; Sawasdee N; Poungvarin N; Junking M; Yenchitsomanus PT Hum Vaccin Immunother; 2020 Oct; 16(10):2318-2327. PubMed ID: 31976810 [TBL] [Abstract][Full Text] [Related]
3. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells. Panya A; Thepmalee C; Sawasdee N; Sujjitjoon J; Phanthaphol N; Junking M; Wongkham S; Yenchitsomanus PT Cancer Immunol Immunother; 2018 Oct; 67(10):1579-1588. PubMed ID: 30056600 [TBL] [Abstract][Full Text] [Related]
5. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
6. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. Strengell M; Lehtonen A; Matikainen S; Julkunen I J Leukoc Biol; 2006 Jun; 79(6):1279-85. PubMed ID: 16551679 [TBL] [Abstract][Full Text] [Related]
7. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. Gilliet M; Liu YJ J Exp Med; 2002 Mar; 195(6):695-704. PubMed ID: 11901196 [TBL] [Abstract][Full Text] [Related]
8. Marina crystal minerals (MCM) activate human dendritic cells to induce CD4+ and CD8+ T cell responses in vitro. Ghoneum MH; Ogura T; Gimzewski JK; Ghoneum AD; Henary MC; Agrawal S Int J Immunopathol Pharmacol; 2018; 32():2058738418797768. PubMed ID: 30270704 [TBL] [Abstract][Full Text] [Related]
9. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
10. Late dendritic cells are still able to evoke a potent alloreactive CTL response. Repnik U; Bergant M; Wraber B; Jeras M Immunobiology; 2008; 213(1):51-64. PubMed ID: 18207027 [TBL] [Abstract][Full Text] [Related]
11. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4⁺ T cell response to β2GPI. Torres-Aguilar H; Blank M; Kivity S; Misgav M; Luboshitz J; Pierangeli SS; Shoenfeld Y Ann Rheum Dis; 2012 Jan; 71(1):120-8. PubMed ID: 21914629 [TBL] [Abstract][Full Text] [Related]
12. STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells. Okada S; Han S; Patel ES; Yang LJ; Chang LJ Immunol Cell Biol; 2015; 93(5):461-71. PubMed ID: 25582338 [TBL] [Abstract][Full Text] [Related]
13. [Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine-induced killer cells]. Li H; Ren XB; Zhang P; An XM; Liu H; Hao XS Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(44):3134-8. PubMed ID: 16405818 [TBL] [Abstract][Full Text] [Related]
14. Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Van Acker HH; Beretta O; Anguille S; De Caluwé L; Papagna A; Van den Bergh JM; Willemen Y; Goossens H; Berneman ZN; Van Tendeloo VF; Smits EL; Foti M; Lion E Oncotarget; 2017 Feb; 8(8):13652-13665. PubMed ID: 28099143 [TBL] [Abstract][Full Text] [Related]
15. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Kim JH; Kang TH; Noh KH; Bae HC; Ahn YH; Lee YH; Choi EY; Chun KH; Lee SJ; Kim TW Clin Exp Immunol; 2011 Aug; 165(2):180-9. PubMed ID: 21592111 [TBL] [Abstract][Full Text] [Related]
16. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. Bodey B; Bodey B; Kaiser HE In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells. Carbonneil C; Saidi H; Donkova-Petrini V; Weiss L Int Immunol; 2004 Jul; 16(7):1037-52. PubMed ID: 15184347 [TBL] [Abstract][Full Text] [Related]
18. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer. Lin CM; Wang FH; Lee PK Clin Immunol; 2002 Jan; 102(1):96-105. PubMed ID: 11781072 [TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Brossart P; Zobywalski A; Grünebach F; Behnke L; Stuhler G; Reichardt VL; Kanz L; Brugger W Cancer Res; 2000 Aug; 60(16):4485-92. PubMed ID: 10969796 [TBL] [Abstract][Full Text] [Related]
20. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Yang AS; Lattime EC Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]